Homology Medicines (NASDAQ:FIXX) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Homology Medicines (NASDAQ:FIXX) from a sell rating to a hold rating in a research note published on Tuesday, Zacks.com reports.

According to Zacks, “Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, insertion and knockout. Homology Medicines Inc. is based in BEDFORD MA. “

A number of other brokerages have also weighed in on FIXX. HC Wainwright set a $4.00 price objective on Uranium Energy and gave the company a buy rating in a report on Tuesday, June 11th. Evercore ISI initiated coverage on Homology Medicines in a research report on Thursday, April 11th. They set an outperform rating and a $29.00 price objective for the company. Finally, ValuEngine raised Alleghany from a hold rating to a buy rating in a research report on Friday, April 19th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $29.10.

FIXX stock traded down $0.15 during midday trading on Tuesday, reaching $20.73. The stock had a trading volume of 14,374 shares, compared to its average volume of 248,227. The firm has a fifty day moving average price of $19.34. The stock has a market cap of $895.83 million, a P/E ratio of -10.37 and a beta of 0.16. Homology Medicines has a 52-week low of $15.07 and a 52-week high of $31.80.

Homology Medicines (NASDAQ:FIXX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.11). The firm had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $1.00 million. Homology Medicines had a negative net margin of 2,253.08% and a negative return on equity of 34.90%. Analysts anticipate that Homology Medicines will post -2.32 EPS for the current fiscal year.

In other news, CEO Arthur Tzianabos sold 12,500 shares of Homology Medicines stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $19.86, for a total value of $248,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Albert Seymour sold 9,300 shares of Homology Medicines stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $19.90, for a total value of $185,070.00. The disclosure for this sale can be found here. Insiders sold a total of 686,600 shares of company stock valued at $14,606,534 in the last quarter. Company insiders own 33.40% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. RTW Investments LP boosted its stake in shares of Homology Medicines by 275.6% in the 4th quarter. RTW Investments LP now owns 1,633,491 shares of the company’s stock valued at $36,525,000 after buying an additional 1,198,574 shares during the period. BlackRock Inc. lifted its stake in Homology Medicines by 134.3% during the fourth quarter. BlackRock Inc. now owns 1,460,449 shares of the company’s stock worth $32,656,000 after purchasing an additional 837,099 shares during the last quarter. Northern Trust Corp lifted its stake in Homology Medicines by 49.6% during the fourth quarter. Northern Trust Corp now owns 181,361 shares of the company’s stock worth $4,055,000 after purchasing an additional 60,163 shares during the last quarter. Global Thematic Partners LLC lifted its stake in Homology Medicines by 22.7% during the first quarter. Global Thematic Partners LLC now owns 165,327 shares of the company’s stock worth $4,585,000 after purchasing an additional 30,551 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Homology Medicines by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 153,033 shares of the company’s stock worth $3,421,000 after purchasing an additional 41,972 shares during the last quarter. Institutional investors and hedge funds own 52.87% of the company’s stock.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Recommended Story: What does an equal weight rating mean?

Get a free copy of the Zacks research report on Homology Medicines (FIXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.